TB-500 + BPC-157

(Combination Protocol)

Source / Derivation:

This formulation combines TB-500, a synthetic fragment of thymosin beta-4 involved in cellular repair and angiogenesis, with BPC-157, a peptide modeled after a gastric-derived protective protein. Together, they integrate two complementary biological systems central to soft-tissue regeneration.

TB-500 + BPC-157

Mechanism of Action:

The combination leverages TB-500’s effects on actin modulation, cell migration, and angiogenesis with BPC-157’s influence on nitric oxide signaling, fibroblast activity, and inflammatory cytokine suppression. The synergy supports coordinated vascular, structural, and inflammatory pathways that underpin efficient tissue repair.

Clinical Relevance & Potential Outcomes:

Research suggests the combined use may enhance recovery of muscle, tendon, ligament, and epithelial tissues, potentially accelerating healing timelines beyond monotherapy. The complementary mechanisms may support improved structural integrity, reduced local inflammation, and more complete functional restoration after injury.

Intended Clinical Application:

Formulation & Quality Specifications:

Delivered as a liquid prefilled pen
Purity: >98% (HPLC-validated)
Storage: 2–8 °C (refrigerated)
Documentation: Full CoA and MSDS available

Concentration:

Frequency:

Dosage (pen clicks):

Duration:

Notes:

5 mg/ml, total 3 ml, total 15 mg

Daily

1 month

Combining TB-500 and BPC-157 offers synergistic effects for tissue healing and recovery.